SCHEMBL25602291

SCHEMBL25602291

O=[N+]([O-])c1ccc2c(c1)C1C=CCC1C(c1ccccc1Cl)N2

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 2/20 0.74
CYBB P04839 1/20 0.70
CA12 O43570 2/20 0.67
CA1 P00915 2/20 0.67
CA2 P00918 2/20 0.67
CA9 Q16790 2/20 0.67
HPN P05981 2/20 0.65
MAPT P10636 4/20 0.61
TP53 P04637 2/20 0.61
GAPDH P04406 1/20 0.60
HSPA1A P0DMV8 1/20 0.60
HSPA8 P11142 1/20 0.60
CD44 P16070 1/20 0.60
MSN P26038 1/20 0.60
PTPN7 P35236 1/20 0.60
EZH2 Q15910 1/20 0.60
NR4A1 P22736 3/20 0.56
KLK3 P07288 1/20 0.54
AR P10275 1/20 0.54
CHRNA7 P36544 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25602306 0.92 CYBB (0.70) USP7CYBBCA12CA1CA2
SCHEMBL16406028 0.85 USP7 (1.00) USP7CYBBCA12CA1CA2
SCHEMBL25602299 0.85 USP7 (0.72) USP7CYBBCA12CA1CA2
SCHEMBL25602301 0.83 USP7 (0.80) USP7CYBBCA12CA1CA2
SCHEMBL25602307 0.83 USP7 (0.87) USP7CYBBCA12CA1CA2
SCHEMBL31277265 0.82 CYBB (1.00) USP7CYBBCA12CA1CA2
SCHEMBL15213475 0.82 CYBB (1.00) USP7CYBBCA12CA1CA2
SCHEMBL13186614 0.79 ESR1 (0.67) CA12CA1CA2CA9MAPT
SCHEMBL16406027 0.79 CYBB (0.84) USP7CYBBHPNMAPTTP53
SCHEMBL2031914 0.79 HPN (1.00) USP7CYBBCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11672794-B2 Therapeutic targeting of the BAP1 complex in cancer NORTHWESTERN UNIVERSITY (US) 2023-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11672794-B2 Therapeutic targeting of the BAP1 complex in cancer BAP1, MCL1, STUB1 USP7 113/4885CYBB 1940/4885CA12 2092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.